Novavax Coronavirus Vaccine Proves ‘Extremely Effective’ in Clinical Trials

Novavax on Monday announced positive results of Phase 3 of its coronavirus vaccine trial, reporting 90.4 percent efficacy overall against the Chinese coronavirus, 93 percent efficacy against what it described as “predominantly circulating Variants of Concern and Variants of Interest,” and 100 percent protection against “moderate and severe disease,” according to the company.

HAMILTON, SCOTLAND - DECEMBER 14: A member of staff receives the Pfizer/BioNTech COVID-19 vaccine at the Abercorn House Care Home on December 14, 2020 in Hamilton, Scotland. (Photo by Russell Cheyne - WPA Pool/Getty Images)